Brokerages expect Heron Therapeutics Inc (NASDAQ:HRTX) to post earnings per share (EPS) of ($0.61) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings. The lowest EPS estimate is ($0.65) and the highest is ($0.56). Heron Therapeutics reported earnings per share of ($0.63) during the same quarter last year, which indicates a positive year over year growth rate of 3.2%. The firm is scheduled to announce its next earnings results on Monday, August 3rd.
On average, analysts expect that Heron Therapeutics will report full-year earnings of ($2.33) per share for the current fiscal year, with EPS estimates ranging from ($2.77) to ($1.41). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.92) per share, with EPS estimates ranging from ($2.00) to $0.19. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.08. Heron Therapeutics had a negative return on equity of 56.85% and a negative net margin of 138.31%. The company had revenue of $25.40 million for the quarter, compared to the consensus estimate of $21.23 million. During the same quarter in the prior year, the company earned ($0.80) earnings per share. Heron Therapeutics’s revenue was down 19.6% on a year-over-year basis.
A number of research firms have weighed in on HRTX. Guggenheim began coverage on Heron Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $24.00 target price on the stock. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, April 15th. Stifel Nicolaus assumed coverage on Heron Therapeutics in a research note on Monday. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, Zacks Investment Research downgraded Heron Therapeutics from a “buy” rating to a “hold” rating and set a $18.00 price objective on the stock. in a research note on Wednesday, May 20th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $36.10.
HRTX stock traded up $0.46 during trading on Tuesday, reaching $14.71. The stock had a trading volume of 4,530,766 shares, compared to its average volume of 1,379,845. Heron Therapeutics has a 52 week low of $9.60 and a 52 week high of $26.81. The stock’s 50 day moving average is $18.34 and its two-hundred day moving average is $18.55. The company has a current ratio of 4.53, a quick ratio of 4.17 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.33 billion, a PE ratio of -6.48 and a beta of 1.55.
A number of institutional investors and hedge funds have recently modified their holdings of HRTX. Sowell Financial Services LLC raised its stake in Heron Therapeutics by 2,443.5% during the 1st quarter. Sowell Financial Services LLC now owns 2,340 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,248 shares during the period. PNC Financial Services Group Inc. raised its stake in Heron Therapeutics by 325.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,698 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 2,064 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in Heron Therapeutics by 259.7% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,579 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 1,862 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Heron Therapeutics by 82.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,896 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 4,463 shares during the period. Finally, X Square Capital LLC bought a new stake in Heron Therapeutics during the 1st quarter valued at approximately $117,000.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Recommended Story: What is the definition of market timing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.